Roche Enhances Diabetes Management with Accu-Chek SmartGuide and mySugr App Integration

Roche has officially received CE Mark approval for its innovative Accu-Chek SmartGuide continuous glucose monitoring (CGM) system, integrating with the widely-used mySugr diabetes management app. This application aims to transform the way people manage diabetes through a more streamlined and effective approach. The integration of applications is set to empower millions of individuals by offering predictive tools that can enhance their health management strategies.

Originally launched back in 2012, mySugr has quickly become renowned across the globe, currently being available in over 84 countries and in 25 different languages. Its user-focused design was developed by individuals with diabetes, making it an accessible and practical solution for managing therapy data and other essential metrics. The newly integrated mySugr Glucose Insights will allow users to analyze their CGM glucose levels comprehensively within the mySugr app, improving user experience by providing key insights on their blood glucose patterns, meal logging, and additional functionalities like insulin dose calculations through the mySugr Bolus Calculator.

The developments were highlighted recently at the European Association for the Study of Diabetes (EASD) annual meeting, showcasing the real-world evidence from the app's rollout. This effort represents Roche's commitment to providing tools that meet the evolving needs of diabetes management. Rodrigo Diaz de Vivar, Lifecycle Leader for Patient Insights at Roche Diagnostics, stated that this integration signifies a positive leap towards patients having peace of mind, attributing an actionable and predictive approach in diabetes management.

The predictive capabilities of the Accu-Chek SmartGuide CGM stand out significantly. This system is the first of its kind to predict glucose levels as far as two hours in advance, thus offering users time to proactively manage their glucose levels and avert potential complications. Dr. Jackie Elliott, Clinical Lead for Diabetes at Sheffield Teaching Hospitals, reinforces the importance of such predictive insights, emphasizing how they can lead patients towards a more manageable daily routine.

Further proving the tool’s efficacy, evaluations revealed its accuracy with a mean absolute relative difference (MARD) of just 9.2%. Over 99% of measured glucose values were found to be within acceptable parameters on the Parkes Error Grid. These statistics reinforce Roche's continuous commitment to delivering advanced technology to optimize diabetes care.

Moreover, real-world data demonstrated that utilizing features like the Night Low Predict significantly decreased the risk of hypoglycemic events. Specifically, it lowered the incidence of Level 1 hypoglycemic events by 20% and Level 2 hypoglycemic risk by 31%, highlighting the tangible benefits of predictive tools in diabetes care.

Since its launch, the Accu-Chek SmartGuide has already made its way into 13 countries, with plans to extend its availability to over 30 countries in Europe, Latin America, and Asia-Pacific by the end of the year. With the integration of such a user-centric solution, Roche aims to minimize barriers to diabetes management, empowering patients with tools to take charge of their health confidently.

By strategically merging CGM technology with the mySugr app, Roche not only enhances real-time tracking of glucose levels but also provides healthcare professionals with a wealth of therapy-related data. This synergy is expected to encourage informed decision-making, ultimately leading to improved health outcomes for individuals living with diabetes.

As Roche continues to expand its offerings in the diabetes space, their goal remains clear: to provide holistic and innovative solutions that benefit people managing diabetes and other related conditions— reaffirming their position as a leader in personalized healthcare. The arrival of the Accu-Chek SmartGuide and its integration with the mySugr app is just the beginning of what's expected to be a transformative journey in diabetes therapy.